The global acute external ventricular drain market size is anticipated to reach USD 643.68 million by 2033, registering a CAGR of 8.85% from 2026 to 2033, according to a new report by Grand View Research, Inc. Rising adoption of conventional over the traditional method, increasing prevalence of acute hydrocephalus, and increasing adoption of technologically advanced devices for acute external ventricular drain are driving the industry’s growth over the forecast period.
External ventricular drains (EVDs) provide benefits for the treatment of acute hydrocephalus. Hydrocephalus is a medical emergency that requires the placement of an EVD into one of the brain's lateral ventricles to drain excess CSF. Each year, 740,000 instances of hydrocephalus in LMICs and about 30,000 in HICs require neurosurgery. Similarly, according to Hydrocephalus Association, hydrocephalus affects about 1 million Americans.
As per the same source, one in every 770 babies develops hydrocephalus in the U.S. Intraventricular hemorrhage is the most frequent cause of acquired hydrocephalus in babies, and studies have indicated that early intervention with an EVD (at the age of 25 days or younger) leads to improved neurological results. Since EVDs are most used in the abovementioned conditions, these factors have directly impacted the industry.
Furthermore, government initiatives such as grant allocation and approval, and investments to identify the most effective care and treatments to aid patient recovery after a brain injury are being implemented in various countries. According to the Hydrocephalus Association, approximately USD 12 million in research was invested in 2021, with an additional USD 35 million in federal funding provided for the study and development of hydrocephalus disease care in Canada.
Additionally, in April 2022, researchers were given a US 2.85 Mn NIH grant to explore a novel method for evaluating cerebrospinal fluid in infants with hydrocephalus. As a result of the aforementioned factors, the market is predicted to increase significantly in the near future.
Request a free sample copy or view report summary: Acute External Ventricular Drain Market Report
By application, Traumatic brain injury dominated the market in 2025, due to the high incidence of road traffic accidents, falls, sports injuries, and violence-related head trauma across both developed and developing regions.
Adult patients dominated the acute EVD market in 2025 due to the higher global burden of neurological disorders requiring intracranial pressure management and cerebrospinal fluid drainage.
North America dominated the acute external ventricular drain market with the revenue share of 35.23% in 2025, driven primarily by the rising incidence of traumatic brain injuries, stroke, and hydrocephalus across the region.
Grand View Research has segmented the global acute external ventricular drain market report based on application, patient type, and region:
Acute EVD Application Outlook (Revenue, USD Million, 2021 - 2033)
Traumatic Brain Injury
Subarachnoid Hemorrhage
Intracerebral Hemorrhage
Other Non-traumatic Hydrocephalus Conditions
Acute EVD Patient Type Outlook (Revenue, USD Million, 2021 - 2033)
Pediatric
Adult
Acute EVD Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Sweden
Denmark
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Acute External Ventricular Drain (EVD) Market
Spiegelberg GmbH & Co. KG (Luciole Medical AG)
Medtronic
Sophysa
Suzhou Yaxin Medical Products Co., Ltd.
Natus Medical Incorporated
Neuromedex GmbH
Integra LifeSciences
Delta Surgical
Möller Medical
B. Braun SE
Fuji Systems
DESU.
"The quality of research they have done for us has been excellent..."